 Significant activity radiographic response rates of approximately 60 has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan CPT-11 and bevacizumab. The 6-month progression-free survival rate is 30 and median survival duration is 9 months. The current first line therapy of GBM patients following initial surgical resectiondebulking is the concomitant use of cerebral radiotherapy and the orally available alkylating agent temozolomide, followed by temozolomide for 6 months post-radiotherapy. 